Jump to main content
Jump to site search

Issue 6, 2014
Previous Article Next Article

The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10

Author affiliations

Abstract

Atovaquone is a front-line antimalarial drug that functions by competitively inhibiting binding of coenzyme Q10 to the cytochrome bc1 complex. Atovaquone is administered orally, but has low solubility and is poorly absorbed with high variability in bioavailability. In vivo binding of human serum albumin has been cited as the major transporter of atovaquone in plasma. The research presented herein demonstrates that saposin B, a known binder/transporter of coenzyme Q10, also binds to atovaquone in a 1 : 1 ratio and with comparably high affinity at pH 5.5.

Graphical abstract: The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10

Back to tab navigation

Publication details

The article was received on 06 Dec 2013, accepted on 25 Feb 2014 and first published on 05 Mar 2014


Article type: Concise Article
DOI: 10.1039/C3MD00373F
Author version available: Download Author version (PDF)
Citation: Med. Chem. Commun., 2014,5, 787-791
  •   Request permissions

    The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10

    B. P. Huta, A. M. Roberts, E. S. Waters, V. Y. Yu, R. P. Doyle, M. R. Mehlenbacher and F. Bou-Abdallah, Med. Chem. Commun., 2014, 5, 787
    DOI: 10.1039/C3MD00373F

Search articles by author

Spotlight

Advertisements